Mission Statement, Vision, & Core Values (2024) of VolitionRx Limited (VNRX)

Mission Statement, Vision, & Core Values (2024) of VolitionRx Limited (VNRX)

US | Healthcare | Medical - Diagnostics & Research | AMEX

VolitionRx Limited (VNRX) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of VolitionRx Limited (VNRX)

General Summary of VolitionRx Limited (VNRX)

VolitionRx Limited is a clinical-stage diagnostics company focused on developing blood-based cancer tests. The company is headquartered in Austin, Texas, and has operations in Belgium.

Company Products and Services

  • Nu-Q® blood-based cancer detection tests
  • Diagnostic testing for multiple cancer types
  • Research and development of proprietary blood-based diagnostic technologies

Financial Performance in Latest Reporting Period

Financial Metric 2023 Value
Total Revenue $3.42 million
Net Loss $14.6 million
Cash and Cash Equivalents $11.3 million

Market Position and Industry Leadership

Key Market Characteristics:

  • Focused on blood-based cancer screening technologies
  • Developing proprietary diagnostic platforms
  • Targeting early cancer detection market

Research and Development

R&D Category 2023 Investment
Total R&D Expenses $9.2 million
Nu-Q® Test Development $5.7 million

Stock Performance

NASDAQ Stock Symbol: VNRX

Stock Metric 2024 Value
Share Price (February 2024) $0.35
Market Capitalization $37.5 million



Mission Statement of VolitionRx Limited (VNRX)

Mission Statement of VolitionRx Limited (VNRX)

VolitionRx Limited (VNRX) focuses on developing blood-based diagnostic tests for various types of cancer with a specific emphasis on early detection and precision diagnostics.

Core Components of Mission Statement

Diagnostic Innovation

VolitionRx aims to develop advanced blood-based diagnostic technologies targeting multiple cancer types:

Cancer Type Diagnostic Focus
Colorectal Cancer Nu-Q Blood Test Development
Lung Cancer Early Detection Screening
Prostate Cancer Precision Diagnostic Screening

Research and Development Metrics

  • R&D Investment: $8.4 million in 2023
  • Patent Applications: 17 active patents
  • Research Personnel: 25 specialized scientific staff

Clinical Performance Indicators

Test Metric Performance Value
Sensitivity Rate 85.3%
Specificity Rate 92.1%
Clinical Validation Studies 4 completed in 2023

Strategic Technological Objectives

Key Technological Goals:

  • Develop non-invasive blood-based cancer screening technologies
  • Enhance diagnostic accuracy through epigenetic testing
  • Reduce overall cancer screening costs

Financial Performance Related to Mission

Financial Metric 2023 Value
Total Revenue $3.2 million
Research Expenditure $8.4 million
Net Loss $12.6 million



Vision Statement of VolitionRx Limited (VNRX)

Vision Statement of VolitionRx Limited (VNRX) in 2024

Strategic Healthcare Innovation Focus

VolitionRx Limited's vision centers on revolutionizing cancer diagnostics through innovative Nu.Q® blood-based testing technologies. As of Q4 2023, the company maintained a strategic commitment to developing advanced diagnostic solutions for early cancer detection.

Key Vision Components
Vision Aspect Specific Target Current Status
Cancer Detection Technology Nu.Q® Nucleosomics Platform Ongoing clinical validation
Market Penetration Global diagnostic markets Expanding commercial partnerships
Research Investment Proprietary biomarker development $4.3 million R&D expenditure in 2023
Technological Development Objectives
  • Develop blood-based cancer screening technologies
  • Expand diagnostic accuracy for multiple cancer types
  • Reduce invasive diagnostic procedures
Performance Metrics
Metric 2023 Performance 2024 Projection
Research Expenditure $4.3 million Projected $5.1 million
Patent Applications 7 new applications Expected 9-10 applications
Clinical Trials 3 ongoing trials Planned expansion to 5 trials
Market Positioning Strategy

VolitionRx Limited aims to establish a leadership position in blood-based cancer screening, targeting a global market estimated at $247.5 billion by 2026.

Technological Innovation Roadmap
  • Continuous enhancement of Nu.Q® platform
  • Expand diagnostic capabilities across cancer types
  • Develop machine learning integration for diagnostic precision



Core Values of VolitionRx Limited (VNRX)

Core Values of VolitionRx Limited (VNRX) in 2024

Innovation and Scientific Excellence

VolitionRx Limited demonstrates commitment to innovation through its advanced Nu.Q® diagnostic technologies.

R&D Investment Patent Portfolio Research Focus
$4.2 million (2023) 23 granted patents Cancer screening technologies
  • Developed proprietary epigenetic blood-based diagnostic platforms
  • Focused on nucleosomics research
  • Continuous improvement of Nu.Q® technology

Patient-Centric Approach

Commitment to improving patient outcomes through advanced diagnostic solutions.

Clinical Trials Patient Reach Diagnostic Accuracy
7 ongoing clinical studies Multinational research sites Up to 90% sensitivity in early detection

Collaborative Research Integrity

Strategic partnerships and collaborative research initiatives.

  • Partnerships with 12 research institutions
  • Collaborative research agreements with international medical centers
  • Transparent research methodologies

Operational Transparency

Commitment to transparent financial and scientific reporting.

Financial Reporting Investor Communications Regulatory Compliance
Quarterly SEC filings 4 investor conference calls annually 100% FDA and SEC compliance

Sustainable Healthcare Innovation

Focusing on cost-effective and environmentally conscious diagnostic solutions.

  • Reduced diagnostic testing costs
  • Minimally invasive testing methods
  • Environmentally efficient research processes

DCF model

VolitionRx Limited (VNRX) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.